Harrow licenses exclusive U.S. rights to BYQLOVI ophthalmic steroid from Formosa

HARROW, INC.

Upfront payment of $500,000 at first commercial sale; additional milestone payments and royalties on gross profits.
BYQLOVI is first new ophthalmic steroid class in over 15 years; FDA-approved for post-op inflammation/pain.
Expected launch in Q4 2025; U.S. market exceeds 7M annual ophthalmic surgeries.
Clinical data: 77-85% pain-free at Day 4; 1.4% elevated IOP; BID dosing 14 days without loading/maintenance.
Formulated with Formosa's proprietary APNT nanoparticle technology.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.